Vacc-4x + Lenalidomide vs. Vacc-4x +Placebo in HIV-1-infected Subjects on Antiretroviral Therapy (ART)

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1/PHASE2

Total Enrollment

36 participants

Study Classification

INTERVENTIONAL

Study Start Date

2012-09-30

Study Completion Date

2014-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

During the course of HIV infection the number of CD4 cells decreases, resulting in a reduced immunological response and ultimately immune deficiency. Vacc-4x is a peptide-based HIV immunotherapy and the primary objective is to strengthen the immune system's response to HIV p24. By adding Lenalidomide, an immunomodulatory agent, as a supporting drug, it is anticipated that the effect of Vacc-4x might be enhanced.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Immunogenicity Study of Vacc-4x Versus Placebo in Patients Infected With HIV

NCT00659789

HIV I Infection

COMPLETED PHASE2

Re-boosting of HIV-1 Infected Subjects With Vacc-4x

NCT01712256

HIV-1 Infection

COMPLETED PHASE2

Intranasal Modified Vacc-4x Gag Peptides With Endocine as Adjuvant

NCT01473810

HIV Infection

COMPLETED PHASE1/PHASE2

A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled HIV-1 Vaccine Trial to Evaluate the Safety and Immunogenicity of rgp120/HIV-1MN (Genentech) in Combination With QS21 Adjuvant and/or Alum in Healthy Adults.

NCT00001044

HIV Infections

COMPLETED PHASE1

Evaluating the Safety, Pharmacokinetics, and Antiviral Activity of a Human Monoclonal Antibody (VRC01) in HIV-Infected Adults Undergoing a Brief Treatment Interruption

NCT02463227

HIV Infections

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Human immunodeficiency virus (HIV) infects the CD4 subset of T-cells that are critical for initiating immune responses to infection. The level of CD4 cells in the blood is a marker of a patient's immunological status. The number of CD4 cells decreases in the course of the HIV infection and results in a reduced immunological response and eventually immune deficiency.

Vacc-4x is one of the few peptide-based therapeutic vaccines tested, and consists of four, slightly modified HIV Gag p24 consensus peptides. Vacc-4x was first tested by intradermal injections using GM-CSF as adjuvant. A recent multinational placebo-controlled study found improvement of vaccine-specific T cell immunity and decrease in viral loads (presented at the AIDS vaccine 2011 conference, Bangkok).

Lenalidomide (CC-5013) is a substance in the class of immunomodulatory agents. The lenalidomide mechanism of action includes anti-neoplastic, pro-erythropoietic, and immunomodulatory properties. Lenalidomide inhibits proliferation of certain hematopoietic tumor cells, enhances T cell- and Natural Killer (NK) cell-mediated immunity and increases the number of NK T cells.

The anti-HIV p24 immune response resulting from Vacc-4x immunization could in combination with ART potentially improve immune reconstitution in patients who have not fully regained a healthy CD4 level (\> 600 x106/L). Adding the immunomodulatory agent Lenalidomide (CC-5013) to Vacc-4x immunization could enhance the immune response to Vacc-4x and further strengthen immune reconstitution.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

HIV-1 Infection

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

SUPPORTIVE_CARE

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Part A: lenalidomide dose escalation

All patient receive intradermal Vacc-4x (1.2 mg) given with Leukine® (rhu-GM-CSF) (0.06 mg) and oral lenalidomide in a dose escalation (3+3) design.

Dose level -1: 2.5 mg Lenalidomide (CC-5013) in the event Dose level 1 is non tolerated dose (NTD) Dose level 1(start): 5 mg Lenalidomide (CC-5013) Dose level 2: 10 mg Lenalidomide (CC-5013) Dose level 3: 25 mg Lenalidomide (CC-5013)

Group Type EXPERIMENTAL

Lenalidomide

Intervention Type DRUG

In Part A a dose escalation design is used (2,5; 5; 10; 25 mg). Part B will use the dose confirmed by Part A

Vacc-4X

Intervention Type DRUG

Vacc-4x is a peptide-based HIV immunotherapy administered intradermally. Vacc-4x peptides are reconstituted in sterile water.

rhuGM-CSF

Intervention Type DRUG

Granulocyte macrophage colony stimulating factor as a local adjuvant

Part B: lenalidomide

Intradermal Vacc-4x (1.2 mg) given with Leukine® (rhu-GM-CSF) (0.06 mg) and oral lenalidomide for 6 immunizations (visit 2, 3, 4, 5, 6 and 7) \& lenalidomide (dose determined in Part A) two days prior to and at the day of immunization.

Group Type EXPERIMENTAL

Lenalidomide

Intervention Type DRUG

In Part A a dose escalation design is used (2,5; 5; 10; 25 mg). Part B will use the dose confirmed by Part A

Vacc-4X

Intervention Type DRUG

Vacc-4x is a peptide-based HIV immunotherapy administered intradermally. Vacc-4x peptides are reconstituted in sterile water.

rhuGM-CSF

Intervention Type DRUG

Granulocyte macrophage colony stimulating factor as a local adjuvant

Part B: lenalidomide placebo

Intradermal Vacc-4x (1.2 mg) given with Leukine® (rhu-GM-CSF) (0.06 mg) and oral lenalidomide for 6 immunizations (visit 2, 3, 4, 5, 6 and 7) \& lenalidomide placebo two days prior to and at the day of immunization.

Group Type PLACEBO_COMPARATOR

Lenalidomide placebo

Intervention Type DRUG

Capsules are identical to the active Lenalidomide capsules used.

Vacc-4X

Intervention Type DRUG

Vacc-4x is a peptide-based HIV immunotherapy administered intradermally. Vacc-4x peptides are reconstituted in sterile water.

rhuGM-CSF

Intervention Type DRUG

Granulocyte macrophage colony stimulating factor as a local adjuvant

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Lenalidomide

In Part A a dose escalation design is used (2,5; 5; 10; 25 mg). Part B will use the dose confirmed by Part A

Intervention Type DRUG

Lenalidomide placebo

Capsules are identical to the active Lenalidomide capsules used.

Intervention Type DRUG

Vacc-4X

Vacc-4x is a peptide-based HIV immunotherapy administered intradermally. Vacc-4x peptides are reconstituted in sterile water.

Intervention Type DRUG

rhuGM-CSF

Granulocyte macrophage colony stimulating factor as a local adjuvant

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Lenalidomide capsule placebo Combination of Vacc-10, Vacc-11, Vacc-12 and Vacc-13. Leukine®

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Men, age ≥ 18 and ≤ 55 years at the time of screening.

Exclusion Criteria

3. Clinically stable on ART for the last 18 months (changes in therapy are allowed as long as the viral load is stable).
4. Well controlled with no treatment failure due to ART resistance in the past
5. Screening plasma viral load (HIV-1 RNA) less than 50 copies/mL for the last six months. If screening value is between 50-500 copies/mL rescreening is allowed. Single blips (up to 500 copies/mL) are allowed.
6. Screening CD4 cell count ≥ 200x10\^6 cells/L and ≤500x10\^6 cells/L. (Rescreening is allowed)
7. Laboratory test results within these ranges: Absolute neutrophil count (ANC) \>1.0x10\^9 /L, Platelet count \>75x10\^9 /L and eGRF (MDRD) \>60 mL/min
8. Signed informed consent
9. Willingness to adhere to Global Pregnancy Prevention Risk Management Plan Lenalidomide

1. Reported pre-study AIDS-defining illness within the previous year
2. Malignant disease.
3. On chronic treatment with immunosuppressive therapy.
4. Autoimmune disorders, present or in the past if there is an increased risk of disease exacerbation.
5. Unacceptable values of the hematologic and clinical chemistry parameters (including those associated with hemophilia), as judged by the Investigator or the Sponsor (or designee), including creatinine values \>1.5x upper limit of normal (ULN), and AST (SGOT), ALT (SGPT), and alkaline phosphatase values \>2.5x ULN.
6. Concurrent chronic active infection such as viral hepatitis B or C or tuberculosis.
7. Previous thromboembolic events or patient is currently immobilized
8. Sexually active subjects who do not adhere to Global Pregnancy Prevention Risk Management Plan Lenalidomide
9. Current participation in other clinical therapeutic studies.
10. Females of childbearing potential will be excluded from this trial. A female of childbearing potential (FCBP) is a sexually mature female who: 1) has not undergone a hysterectomy or bilateral oophorectomy; or 2) has not been naturally postmenopausal (amenorrhea following cancer therapy does not rule out childbearing potential) for at least 24 consecutive months (i.e. has had menses at any time in the preceding 24 consecutive months).
11. The development of erythema nodosum if characterized by a desquamating rash while previously
12. Incapability of compliance to the treatment protocol, in the opinion of the Investigator.

Minimum Eligible Age

18 Years

Maximum Eligible Age

55 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No